Zaiding pharmaceutical and bringer Ingelheim reached a CMO cooperation on a new monoclonal antibody

Today, Germany's pharmaceutical giant bringer Ingelheim signed a strategic cooperation agreement with zaiding Pharmaceutical Co., Ltd located in Zhangjiang, Shanghai, to provide technology optimization and manufacturing services for the new monoclonal antibody of zaiding pharmaceutical, which will be used to treat autoimmune diseases "The strategic cooperation with zaiding pharmaceutical is another important milestone in the development of our biopharmaceutical business in China," said Dr Luo Jiali, general manager of bringer Ingelheim biopharmaceutical (China) Co., Ltd We believe that through our advanced biopharmaceutical technology and quality management system, we can promote the R & D and marketing of zaiding pharmaceutical in the field of immune diseases " Before that, in 2013, bringer Ingelheim and Shanghai Zhangjiang biomedical Base Development Co., Ltd jointly built the first and currently the only biopharmaceutical base with international standards for multinational pharmaceutical enterprises in China Through the base, Boehringer Ingelheim hopes to become the first international provider of biopharmaceutical contract production scheme in China, providing customers with all-round services from production process development, clinical research samples to commercial supply In June 2015, bringer Ingelheim and Pudong New Area Government signed the memorandum of understanding on promoting biopharmaceutical manufacturing industry The company plans to continue to invest more than 100 million euros in the next five years for the construction and operation of China's biopharmaceutical base At present, the pilot plant of the base for toxicology research sample production and early clinical supply has been put into operation, and it has been selected as the first pilot enterprise to carry out biopharmaceutical contract production (CMO) in China Commercial supply is expected to be officially put into production in the first quarter of 2017 The first product of the pilot project is a new immunoantitumor drug independently developed by Baiji Shenzhou Institute, which is closely related to bringer Ingelheim.